IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
Lymphoma, T-Cell|Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides/Sezary Syndrome
BIOLOGICAL: IPH4102
Objective Response Rate (ORR), Using the Olsen (2011, JCO) criteria (All cohorts), From the first dose until study completion, an expected average of 2 years
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) (All cohorts), patients with treatment-related adverse events as assessed by CTCAE v5.0, From first dose until study completion, an expected average of 2 years|Quality of life (QoL) (All cohorts), Using the Skindex29 questionnaire to assesse the effects of skin disease on quality of life in three domains: Symptoms, Emotions, and Functioning, Through study completion, an expected average of 2 years|pruritus (All cohorts), Using Visual Analog Scale (VAS) for prutitus assessment: From 0 = No pruritus to 10 = Pruritus as bad as it could possibly be, Through study completion, an expected average of 2 years|ORR using blinded central review (Cohort 1), Using the Olsen (2011, JCO) criteria, From the first dose until study completion, an expected average of 2 years|Progression free survival (PFS) (All cohorts), From the first dose until study completion, an expected average of 2 years|Overall survival (OS) (All cohorts), From the first dose until study completion, an expected average of 2 years|PK parameters : Maximum Plasma Concentration of IPH4102 alone (All cohorts), Maximum Plasma Concentration (Cmax) (W1, W5), From the first dose until study completion, an expected average of 2 years|PK parameters :Trough Concentration of IPH4102 alone (All cohorts), Trough Concentration (Ctrough) every 8 or 12 weeks, From the first dose until study completion, an expected average of 2 years|Immunogenicity of IPH4102 alone (All cohorts), A serum sample will be collected at the specified time points for evaluation of anti-drug antibodies (ADA)., From the first dose until study completion, an expected average of 2 years|Duration of Response (DOR), From the first dose until study completion, an expected average of 2 years
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.